Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Priming the Tumour Microenvironment for Immunotherapy in Locally Advanced Rectal Cancer (Durvalumab + Extended Neoadjuvant Regimens)
2019-001471-36Phase 2Unknown
- Sponsor
- NHS Greater Glasgow and Clyde
- Start
- Aug 2020
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of durvalumab in rectal cancer (2 arms), sponsored by NHS Greater Glasgow and Clyde. Primary endpoint: Proportion of patients achieving complete clinical or pathological response at 6 months. Status: unknown.
02
Drugs
durvalumab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on 2019-001471-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001471-36.